Osteoarthritis affects almost 21 million Americans aged 25 or older, and is most prevalent in the hand. The need for an alternative to long-term drug therapy for treating early stage hand OA is a vastly underserved market that Silicon Valley-based Articulinx Inc. hopes to address with its Intercarpometacarpal Cushion, a spacer device used to augment cartilage in the basal joint of the thumb.
1601 South De Anza Boulevard
Suite 215
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.
Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.
The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.
